Results 21 to 30 of about 1,090 (156)

Awareness of EUGOGO guidelines and attitudes regarding smoking in Graves' orbithopathy in Croatia

Taiwan Journal of Ophthalmology, 2022
It is a common knowledge that Graves' disease is the most frequent cause of hyperthyroidism ; it also affects other organs including eyes and skin. Thyroid-associated ophthalmopathy, an autoimmune inflammatory condition, affects 25%– 50% of patients with Graves' disease.
Baretic Maja, Juri Mandic Jelena, Kusacic Kuna Sanja, Gudelj Lara, Radic Marija, Zlatar Mirna   +5 more
doaj   +3 more sources

The relationship between cholesterol levels and thyroid eye disease [PDF]

European Thyroid Journal
Background: Thyroid eye disease (TED) is the most prevalent extrathyroidal manifestation of Graves’ disease (GD). Emerging evidence suggests a relationship between elevated total and low-density lipoprotein (LDL) cholesterol levels and TED.
Caroline Cardo, Roberto Bernardo Santos, Ana Beatriz Pinotti Pedro Miklos, Sabrina Barbosa Jaconis, João Hamilton Romaldini, Danilo Villagelin   +5 more
doaj   +2 more sources

Real world effectiveness of Mycophenolate-sodium therapy in patients at risk with Graves’ orbitopathy [PDF]

Thyroid Research
Purpose Patients with active, moderate-to-severe Graves’ orbitopathy require immunosuppressive treatments to reduce inflammation and morbidity. Since 2021 EUGOGO lists Mycophenolate-sodium (MPS) as first-line-treatment, which lead to a change in ...
Julius Sander, Karim Al-Ghazzawi, Nikolaos Bechrakis, Ying Chen, Inga Neumann, Anja Eckstein, Michael Oeverhaus   +6 more
doaj   +2 more sources

Response to comment by Smith on the 2021 EUGOGO guidelines [PDF]

European Journal of Endocrinology, 2021
n ...
Kahaly, George J, Bartalena, Luigi
openaire   +3 more sources

Evolution des volumes musculaires orbitaires sous traitement par protocole EUGOGO dans l'orbitopathie basedowienne active

Objectif : évaluer l’impact du protocole EUGOGO sur le volume musculaire orbitaire dans l’orbitopathie basedowienne modérée à sévère active. Méthode : il s’agit d’une étude observationnelle, monocentrique, rétrospective, incluant 20 patients soit 40 orbites, ayant bénéficié entre juin 2021 et février 2024 d’un traitement par corticothérapie intra ...
Aubeleau, Mathilde
openaire   +2 more sources

The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy [PDF]

European Journal of Endocrinology, 2021
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease (GD). Choice of treatment should be based on the assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most patients with GO.
L Bartalena, G J Kahaly, L Baldeschi, C M Dayan, A Eckstein, C Marcocci, M Marinò, B Vaidya, W M Wiersinga, _ _, _ _, Goksun Ayvaz, Onur Konuk, Jasmina Ciric, Bijliana Beleslin, Antonella Boschi, Maria Cristina Burlacu, Dan Morris, Rosario Le Moli, Antonio Marino, Justin McKee, Nicola Zammit, Dagmar Führer, Ioana Pereni, Michael Schittkowski, Dirk Raddatz, Vickie Lee, Karim Meeran, Juliette Abeillon, Thia Soui Thcong, Katharina Ponto, Ilaria Muller, Nicola Currò, Christoph Hintschich, Roland Gärtner, Simon Pearce, Lucy Clarke, Thomas Brix, Dorte Bechtold, Gottfried Rudovfsky, Nicole Fichter, Laurence Du Pasquier, Julia Meney, Francesca Menconi, Giulia Lanzolla, Gangadhara Sundar, Samantha Peiling Yung, Kostas Boboridis, Panagiotis Anagnostis, Marta Pérez Lopez, Carlos Javier Sanchez, Maria Laura Tanda, Simone Donati, Andrea Papp, Shuren Li, Anna Jablonska, Piotr Miskiewicz, Jelena Juri Mandic, Maja Baretic   +58 more
openaire   +7 more sources

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO [PDF]

European Journal of Endocrinology, 2008
Summary of consensus a. All patients with GO should (Fig. 1):Be referred to specialist centers;Be encouraged to quit smoking;Receive prompt treatment in order to restore andmaintain euthyroidism.b. Patients with sight-threatening GO should be treatedwith i.v.
Bartalena L, BALDESCHI, LELIO, Dickinson A, Eckstein A, Kendall Taylor P, MARCOCCI, CLAUDIO, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, MARINO', MICHELE, NARDI, MARCO, Neoh C, Orgiazzi J, Pearce S, PINCHERA, ALDO, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM, European Group on Graves' Orbitopathy   +28 more
openaire   +3 more sources

Treatment of ophthalmopathy in the course of Graves’ disease

Journal of Education, Health and Sport, 2019
: Introduction: Graves’ disease is an autoimmune disease in which the TSH receptor (TSHR) is an autoantigen. Its stimulation by antibodies inhibiting thyrotropin binding causes increased secretion of free thyroid hormones and consequently symptoms of ...
Magdalena Woźniak, Ewa Tywanek, Grzegorz Rudzki, Joanna Świrska, Agnieszka Zwolak, Robert Jan Łuczyk   +5 more
doaj   +3 more sources

Clinical profile of thyroid eye disease and factors predictive of disease severity

Indian Journal of Ophthalmology, 2020
Purpose: To describe the clinical features of thyroid eye disease (TED) in patients presenting at a tertiary eye care centre in North India and to identify factors predictive of severe disease.
Alankrita Muralidhar, Sima Das, Sweety Tiple   +2 more
doaj   +1 more source

Application of Multiparameter Quantitative Magnetic Resonance Imaging in the Evaluation of Graves' Ophthalmopathy

Journal of Magnetic Resonance Imaging, Volume 58, Issue 4, Page 1279-1289, October 2023., 2023
Background Assessment of the activity of Graves' ophthalmopathy (GO) is difficult. Existing methods need improvement. Purpose Investigate the application of multiparametric magnetic resonance imaging (MRI) in GO. Study Type Retrospective. Population A total of 235 GO patients (age: 38.8 ± 13.4 years; 90 male; 96 active patients).
Zhangfang Li, Yaosheng Luo, Xiaoting Feng, Qing Zhang, Qiang Zhong, Chanyan Weng, Zhi Chen, Jie Shen   +7 more
wiley   +1 more source